What is NDC 61755-005?

61755-005 is the product NDC for Eylea (aflibercept), Aflibercept 40 mg/mL injection, solution, listed with the FDA by Regeneron Pharmaceuticals, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.

Regeneron Pharmaceuticals, Inc., NDC labeler code 61755. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Eylea?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Yes: J0178, Injection, aflibercept, 1 mg.

Eylea NDC 61755-005 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)61755-005Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61755-0005Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
61755-005-01	61755000501	1 SYRINGE, GLASS in 1 CARTON (61755-005-01) / .05 mL in 1 SYRINGE, GLASSMarketed from Dec 9, 2019
61755-005-02	61755000502	1 VIAL, SINGLE-USE in 1 CARTON (61755-005-02) / .05 mL in 1 VIAL, SINGLE-USEMarketed from Nov 21, 2011
61755-005-54	61755000554	1 SYRINGE, GLASS in 1 CARTON (61755-005-54) / .05 mL in 1 SYRINGE, GLASSMarketed from Dec 9, 2019
61755-005-55	61755000555	1 VIAL, SINGLE-USE in 1 CARTON (61755-005-55) / .05 mL in 1 VIAL, SINGLE-USEMarketed from Jan 16, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Eylea
Generic name (nonproprietary): aflibercept
Active ingredients: Aflibercept — 40 mg/mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: Regeneron Pharmaceuticals, Inc.NDC labeler code 61755
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125387
Marketing start: Nov 21, 2011
Listing expires: Dec 31, 2027
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers: Product ID 61755-005_9e18f393-aea5-48ef-8ac9-7d523f0badc0SPL ID 9e18f393-aea5-48ef-8ac9-7d523f0badc0SPL set ID f96cfd69-da34-41ee-90a9-610a4655cd1cRxCUI 1232154, 1232159, 2693564, 2693567UNII 15C2VL427D
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0178 — Injection, aflibercept, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

EYLEA HD has its own HCPCS code.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N461755000501 followed by a unit qualifier and the quantity

Package 61755-0005-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 7, 2026.

Indications (excerpt from the label)

EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of Prematurity (ROP)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 61755-005

What is NDC 61755-005?: 61755-005 is the product NDC for Eylea (aflibercept), Aflibercept 40 mg/mL injection, solution, listed with the FDA by Regeneron Pharmaceuticals, Inc.. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Eylea (Aflibercept).
What is the active ingredient?: Aflibercept.
Who is the labeler?: Regeneron Pharmaceuticals, Inc., NDC labeler code 61755. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Eylea?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Yes: J0178, Injection, aflibercept, 1 mg. See Billing references above.

Eylea (Aflibercept) NDC 61755-005